Amgen's Repatha lowers heart attack risk 20% versus ezetimibe in real-world study

AMGN•2026-11-05

Amgen said Repatha lowered fatal or nonfatal heart attack risk by 20% versus ezetimibe in a real-world study of 544,103 adults followed for up to four years.

Amgen's Repatha lowers heart attack risk 20% versus ezetimibe in real-world study

1. Study findings

Related News

Keel Infrastructure publishes Q3 2026 earnings call transcript

Private markets investors favor smaller managers, SS&C Intralinks survey finds

US worker productivity surges in third quarter

DXP Enterprises publishes Q3 2026 results presentation

Morgan Stanley cuts Cava Group target price to $85 from $90